We appreciate the response to our editorial.1 The robust results achieved by neurofilament light chain (NfL) are paving the way toward its clinical implementation. Neurologists need to figure out how best to use NfL in clinical practice. The analogy with other markers routinely used in other areas may be of help. C-reactive protein (CRP) is a nonspecific marker of inflammation; it provides an alert, which prompts the doctor to proceed with additional necessary examinations to reach a diagnosis. The strength of the analogy with NfL relies on CRP’s nonspecific but very sensitive and reliable indication of an underlying pathologic process. Nevertheless, other markers of organ damage could be used, such as liver transaminases, troponin, or creatine kinases. The analogy between NfL and each of these could be also acceptable.
